The U.S. Food and Drug Administration approved for sale a kidney-cancer drug thatAG hopes to eventually expand to a variety of other cancers.
It’s been a dream for a decade: a single daily pill combining aspirin, cholesterol medicine and blood pressure drugs — everything people need to prevent heart attacks and strokes in a cheap, generic form.
A global team of cancer researchers published an exciting new study in the Journal of the American Chemical Society this week, showing that zoledronate, a new type of bisphosphonate drug, when combined with hormone therapy, reduced the recurrence of breast cancer in pre-menopausal women at a significant rate. Researchers found this new drug agent is nearly 200 times more powerful at killing cancer cells than previous drugs. This is astounding news for the nearly 200,00 women and men diagnosed with breast cancer every year, and the nearly 50,000 that lose their battle with the disease. Read more
Human trials under way at the University of Miami and other hospitals in Europe, Asia and Latin America using immature adult stem cells are showing promise for people with type 2 diabetes.
Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have identified a new marker for breast cancer metastasis called TMEM, for Tumor Microenvironment of Metastasis. As reported in the March 24 online edition of the journal Clinical Cancer Research, density of TMEM was associated with the development of distant organ metastasis via the bloodstream â€” the most common cause of death from breast cancer.
Drug showed 90 percent kill of leukemic stem cells and prolonged survival in mice with resistant CML
Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are the subject of an advance online publication in the journal Leukemia, ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today. The findings of this study provide new insights into the problem of minimal residual disease and may open the door to the development of a curative treatment strategy for some patients with CML.
Looking for a better treatment for the autoimmune disease myasthenia gravis, researchers have found that a protein in tick saliva shows promise in limiting the severity of the disease in an animal model in a study published in the Annals of Neurology.
A study will be published on March 21, 2009 in World Journal of Gastroenterology addresses the question. A research group in King Saud University, Kingdom of Saudi Arabia investigated, for the first time, the role of carnitine, a naturally occurring compound that is synthesized mainly in the liver, during the development of hepatocarcinogenesis. Authors of the study reported that carnitine deficiency is a risk factor and should be viewed as a mechanism in hepatic carcinogenesis, and that long-term L-carnitine supplementation prevents the development of liver cancer. Therefore, carnitine supplementation alone or in combination with other natural chemopreventive compounds could be used to prevent, slow or reverse the occurrence of liver cancer.
Relying on principles similar to those that cause Jell-O to congeal into that familiar, wiggly treat, University of Michigan researchers are devising a new method of detecting nitric oxide in exhaled breath.